Molecular and clinical determinants of drug-induced long QT syndrome: An iatrogenic channelopathy

Swiss Medical Weekly

Volumn 134, Issue 47-48, 2004, Pages 685-694

  Abriel, Hugues ^a,b   Schläpfer, Jürg ^a   Keller, Dagmar I ^a,c   Gavillet, Bruno ^b   Buclin, Thierry ^a   Biollaz, Jérôme ^a   Stoller, Rudolf ^d   Kappenberger, Lukas ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d Swissmedic   (Switzerland)

Author keywords

Adverse drug reaction; Arrhythmias; Long QT syndrome; Pharmacogenetics; Torsades de pointes

Indexed keywords

ADRENALINE SINTETICA; AMIODARONE; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIMALARIAL AGENT; CARDIOVASCULAR AGENT; CHLORAL HYDRATE; CHLORPROMAZINE; CITALOPRAM; CITALOPRAM MEPHA; CLOMIPRAMINE; DISOPYRAMIDE; DISOPYRAMIDE PHOSPHATE; DOBUTAMINE; DOPAMINE; DOXEPIN; DROPERIDOL; EPHEDRIN STREULI; EPHEDRINE; FELBAMATE; FLECAINIDE; FLECAINIDE ACETATE; FLUDAPAMIDE; FLUOXETINE; FLUPENTIXOL; IBUTILIDE; IBUTILIDE FUMARATE; INDAPAMIDE; ISRADIPINE; KINIDIN DURILES; LOMIR SRO; MAGNESIUM SULFATE; MEPIVACAINE; MIDODRINE; NEUROTROPIC AGENT; NORADRENALIN; QUINIDINE; SOTALOL; UNINDEXED DRUG;

CONGENITAL DISORDER; DRUG INDUCED DISEASE; DRUG INFORMATION; DRUG WITHDRAWAL; ERG CHANNEL; FOOD DRUG INTERACTION; GENDER; GENE MUTATION; GENETIC SCREENING; HEART DISEASE; HEART REPOLARIZATION; HEREDITY; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; IATROGENIC CHANNELOPATHY; IATROGENIC DISEASE; MEMBRANE CHANNEL; MOLECULAR BIOLOGY; NORMAL VALUE; POTASSIUM CURRENT; QT PROLONGATION; REVIEW; RISK FACTOR; SUDDEN DEATH; SWITZERLAND; TORSADE DES POINTES;

EID: 11144320454     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999; 354:1625-33.
2. Roden DM. Drug-Induced Prolongation of the QT Interval. N Engl J Med 2004;350:1013-22.
3. Fenichel RR, et al. Drug-Induced Torsades de Pointes and Implications for Drug Development. J Cardiovascular Electrophysiol 2004;15:475-95.
4. Tartini R, Kappenberger L, Steinbrunn W, Meyer UA. Dangerous interaction between amiodarone and quinidine. Lancet 1982;1:1327-9.
5. Woosley RL. Cardiac actions of antihistamines. Ann Rev Pharmacol Toxicol 1996;36:233-52.
6. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy 2001;21:1468-72.
7. Violand C, Piguet V. Methadon - dosisabhängiges Risiko von Torsade de pointes/Kammertachykardien und QT-Verlängerung. Swissmedic Journal 2004;3:17-8.
8. Roden DM, Balser JR, George AL Jr, Anderson ME. Cardiac ion channels. Ann Rev Physiol 2002;64:431-75.
9. Kearing MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104:569-80.
10. Weidmann S. Effect of current flow on the membrane potential of cardiac muscle. J Physiol 1951;115:227-36.
11. Kass RS. (Genetically induced reduction in small currents has major impact. Circulation 1997;96:1720-1.
12. Numaguchi H, et al. Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circ Res 2000; 87:1012-8.
13. MacNeil DJ. The side effect profile of class III antiarrhythmic drugs: focus on d,1-sotalol. Am J Cardiol 1997;80:90G-98G.
14. Splawski I, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000;102:1178-85.
15. Romano C, Gemme G, Pongiglione & R. Aritmie cardiache rare dell'età pediatrics. Clin pediat 1963;45:656-83.
16. Ward OC. A new familial cardiac syndrome in children. J Irish Med Assoc 1964;54:103-6.
17. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval, and sudden death. Am Heart J 1957;54:59-68.
18. Schwartz PJ, Priori SG, Napolitano C. The Long QT Syndrome. In: Cardiac Electrophysiology: From Cell to Bedside (Zipes DP, Jalife J, eds.), 2000 pp. 597-615. W.B. Saunders Company, Philadelphia.
19. + channel structure-activity relationships and mechanisms of drug-induced QT prolongation. Annu Rev Pharmacol Toxicol 2003;43:441-61.
20. Study group on molecular basis of arrhythmias. Inherited Arrhythmias Database. 2004. http://pc4.fsm.it:81/cardmoc/, accessed September 7, 2004.
21. Volders PG, et al. Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. Cardiovasc Res 2000;46:376-92.
22. Vos MA, van Opstal JM, Leunissen JD, Verduyn SC. Electrophysiologic parameters and predisposing factors in the generation of drug-induced Torsade de Pointes arrhythmias. Pharmacol Ther 2001;92:109-22.
23. Bazett HC. An analysis of the time relations of the electrocardiograms. Heart 1920;7:353-70.
24. Stramba-Badiale M, Locati EH, Martinelli A, Courville J, Schwartz PJ. Gender and the relationship between ventricular repolarization and cardiac cycle length during 24-h Holter recordings. Eur Heart J 1997;18:1000-6.
25. Committee for Proprietary Medicinal Products. Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products. 1997. http://www.emea.eu.int/pdfs/human/swp/098696en.pdf, accessed September 7, 2004.
26. Roden DM. Pharmacogenetics and drug-induced arrhythmias. Cardiovasc Res 2001;50:224-31.
27. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996;94:1471-4.
28. Drici MD, Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001;24:575-85.
29. Schulze-Bahr E, Haverkamp W, Eckardt L, Kirchhof P, Wedekind H, Breithardt G. Genetic aspects in acquired long QT syndrome - A piece in the puzzle. Eur Heart J Supplements 2001;Supplement K:K48-K52.
30. Yang P, et al. Allelic variants in long-QT disease genes in patients with drug- associated torsades de pointes. Circulation 2002;105:1943-8.
31. Donger C, et al. KVLQT1 C-Terminal Missense Mutation Causes a Forme Fruste Long-QT Syndrome. Circulation 1997; 96:2778-81.
32. Piippo K, et al. Effect of the antimalarial drug halofantrine in the long QT syndrome due to a mutation of the cardiac sodium channel gene SCN5A. Am J Cardiol 2001;87:909-11.
33. Makita N, et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation 2002;106:1269-74.
34. Napolitano C, et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000;11:691-6.
35. Marban E. Cardiac channelopathies. Nature 2002;415:213-8.
36. Davey PP, Barlow C, Hart G. Prolongation of the QT interval in heart failure occurs at low but not at high heart rates. Clin Sci (Colch.) 2000;98:603-10.
37. Schwartz PJ, Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction Circulation 1978;57:1074-7.
38. Dekker JM, Crow RS, Hannan PJ, Schouten EG, Folsom AR. Heart rate-corrected QT interval prolongation predicts risk of coronary heart disease in black and white middle-aged men and women: the ARIC study. J Am Coll Cardiol 2004;43:565-71.
39. Glancy JM, Garratt CJ, Woods KL, de Bono DR QT dispersion and mortality after myocardial infarction. Lancet 1995; 345:945-8.
40. Maron BJ, et al. Assessment of QT dispersion as a prognostic marker for sudden death in a regional nonreferred hypertrophic cardiomyopathy cohort. Am J Cardiol 2001;87:114-5, A9.
41. Kurita T, et al. Bradycardia-induced abnormal QT prolongation in patients with complete atrioventricular block with torsades de pointes. Am J Cardiol 1992;69:628-33.
42. Strasberg B, et al. Polymorphous ventricular tachycardia and atrioventricular block. Pacing Clin. Electrophysiol 1986;9:522-6.
43. Ishida S, Takahashi N, Nakagawa Al, Fujino T, Saikawa T, Ito M. Relation between QT and RR intervals in patients with bradyarrhythmias. Br Heart J 1995;74:159-62.
44. Numaguchi H, Johnson JP Jr, Petersen CI, Balser JR. A sensitive mechanism for cation modulation of potassium current. Nat Neurosci 2000;3:429-30.
45. Fenichel RR. Development of drugs that alter ventricular repolarization. Am J Ther 2002;9:127-39.
46. Paul AA, Witchel HJ, Hancox JC. Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol 2002;136:717-29.
47. Sarubbi B, Ducceschi V, Briglia N, Mayer MS, Santangelo L, Iacono A. Compared effects of sotalol, flecainide and propafenone on ventricular repolarization in patients free of underlying structural heart disease. Int J Cardiol 1998;66:157-64.
48. Benhorin J, et al. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation 2000;101:1698-706.
49. Abriel H, Wehrens XHT, Benhorin J, Kerem B, Kass RS. Molecular pharmacology of the sodium channel mutation D179OG linked to the long QT syndrome. Circulation 2000;102:921-5.
50. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA 1994;91:3438-42.
51. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Kearing MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
52. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299-307.
53. Chen J, Seebohm G, Sanguinetri MC. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc Natl Acad Sci USA 2002;99:12461-6.
54. + channel block. J Biol Chem 2002;277:23587-95.
55. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetri MC. A structural basis for drug-induced long QT syndrome. Proc Nad Acad Sci USA 2000;97:12329-33.
56. Zeltser D,Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 2003;82:282-90.
57. Haverkamp W, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs; clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000;21:1216-31.
58. Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. Progress in Cardiovascular Diseases 2003;45:415-27.
59. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998;46:101-10.
60. Tzivoni D, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 1988;77:392-7.
61. Kerr GW, McGuffie AC, Wilkie S. Tricyclic antidepressant overdose: a review. Emerg Med J 2001;18:236-41.
62. Plaster NM, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001;105:511-9.
63. Marks ML, Whisler SL, Clericuzio C, Keating MT. A new form of long QT syndrome associated widi syndactyly. J Am Coll Cardiol 1995;25:59-64.